Share Name Share Symbol Market Type Share ISIN Share Description
Vernalis LSE:VER London Ordinary Share GB00B3Y5L754 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.40p +4.99% 8.42p 8.16p 8.66p 8.20p 7.92p 7.92p 219,686 16:35:29
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 12.0 -15.3 -3.2 - 44.33

Vernalis Share Discussion Threads

Showing 3426 to 3450 of 3450 messages
Chat Pages: 138  137  136  135  134  133  132  131  130  129  128  127  Older
DateSubjectAuthorDiscuss
18/1/2018
17:42
Most severe flu in a hundred years and they still fail to achieve the exponential increase in scrips required to justify their strategy. Tuzistra XR is by now clearly a hopeless product, an expensive option in a market dominated by cheap quick fixes and a political environment hostile to costly drugs and codiene based formulations. Management should all be sacked for having missed the opportunity to sell three products into this severe cold and flu season.
romeike
19/12/2017
11:35
I agree with romeike 100% - personally I wouldn't buy in either even at this level - I can't see any positives at all any more - maybe someone else can. imho fwiw nai
bountyhunter
18/12/2017
16:23
Maybe sell the 'rights' to either Tris or a US based company to recover some of the development money?
fhmktg
18/12/2017
16:20
I wouldn't buy in mate - even if they pulled off their stated strategy in terms of product launches (which is already massively off track), I think they'd still be struggling to bring in enough cash to pay their outrageously expensive CEO. It very much looks like 5 years from now they'll have some of the intended products on the market generating small surplus revenues that will constitute a small fraction of the many, many millions of dollars put into getting them there. They'd be better to dump the sales team, cancel the products altogether and put the cash they have now into making their research business properly profitable.
romeike
18/12/2017
12:01
Any views here -is this cheap or just a real crock?
meijiman
14/12/2017
18:27
Interesting but please explain relevance here?
bountyhunter
14/12/2017
18:20
Around 1 in every 1500 people alive in the UK are CJD carriers Prion disease is CJD It takes decades to activate in most cases In some cases gene dependent , it can activate sooner In some cases it never activates Nearly 35% of people that are carriers will activate IF they live long enough ie over 85 plus Prion Protein Disease is the root cause of Alzheimer's , Huntingdon's, Parkinsons, Dementia and others Prion-like Behavior in the Huntingtin Protein By ocords 06 May, 2015 Protein Aggregation Prion-Like Behavior in the Huntingtin Protein: Protein aggregates are a hallmark feature of Huntington’s disease (HD)[1], as well as a number of other neurodegenerative diseases. These protein aggregates, composed of misfolded proteins that clump together, are traditionally thought to develop in vulnerable neurons individually. However, recent research suggests that these misfolded proteins may be transmitted from neuron to neuron. Is Parkinson’s A Prion Disease? By Neuroskeptic | October 14, 2017 The Journal of Neuroscience recently featured a debate over the hypothesis that Parkinson’s disease is, at least in some cases, caused by a prion-like mechanism – misfolded proteins that spread from neuron to neuron. Prion-like propagation of mutant SOD1 misfolding and motor neuron disease spread along neuroanatomical pathways. Ayers JI1, Fromholt SE2, O'Neal VM2, Diamond JH2, Borchelt DR2,3. A hallmark feature of amyotrophic lateral sclerosis (ALS) is that symptoms appear to spread along neuroanatomical pathways to engulf the motor nervous system, suggesting a propagative toxic entity could be involved in disease pathogenesis. Are Prions behind All Neurodegenerative Diseases? Evidence mounts that chain reactions involving toxic proteins link Creutzfeldt–Jakob disease, Alzheimer’s, Parkinson’s and more
buywell3
14/12/2017
14:40
Who is the Chairman? -it's his job to get rid of an underperforming ceo. Woodford has completely lost the plot.
meijiman
14/12/2017
14:25
I got out in the late 40's, why Woodford held on is beyond me?
cockneytrader
14/12/2017
13:21
The share price has gone from 86p to 8.6p in just over two years under the stewardship of Ian Garland. In any other line of work such an incompetent managerial record would result in the sack.
lcwanderer
14/12/2017
09:17
Sold out the last of this today, this has turned into one right DOG of a stock. Far better opportunities available elsewhere and looks like it is going to be blunder after blunder into crisis here. An over reliance on releasing expensive products into a rapidly declining market that more than ever is looking at costs and opiate dependency is just not a go-er.
romeike
14/12/2017
08:52
Only 85% increase in prescriptions isn't good enough at this point, there's an awful lot now resting on this winter season to try and prove this product can sell. Interesting that the company is so focused on numbers of prescriptions rather than actual sales revenue. Company needs to reconsider if it is worth releasing the remaining narcotic based products at all. Looks like little real progress on other areas of the strategy.
romeike
12/12/2017
12:02
That's me out with a profit of £85. Should be enough to cover the cost of a trip to the Museum of Agriculture and the Preservation of ponies
cromwells revenge
12/12/2017
11:57
Tris have a blanket policy on non-disclosure, I doubt that we will see any more information coming out. Think this share is definitely one for the bottom drawer. If they turn things around then fantastic but for now it looks bad, though I think the current share price probably overstates how bad.
romeike
05/12/2017
14:14
@hvs Cash burn is far too high given the situation - they have positioned for selling four products, and were counting on those extra revenues to pay for it all, but the reality now is that the sales team are only selling one product, and one that while selling at decent volume is returning less revenues than forecast, presumably due to a greater than expected reliance on coupons and sampling. As it stands the current set up is completely unsustainable. 6 months on from the first failure there is no news on resubmission of the new products and equally Garland has now certainly broken his 12 month promise (later revised to 18 months) to sort out Moxatag supply. Yes there has been some suggestion of a resolution but no details released that would indicate if the product will even make a material return for Vernalis under the new supply arrangements. From an investment point of view a disaster isn't even required by the way, stagnation is bad enough when there are so many other successful companies with effective management teams out there led by better CEOs on much smaller remuneration. The recent hammering of pharma companies like Shire, GSK and Allergan provides an excellent opportunity to reduce and derisk here and make up the losses elsewhere.
romeike
23/11/2017
11:19
No cashNo credibility with customersNo credibility in the financial market$60 million of cash burnt.
fhmktg
23/11/2017
09:08
If there is any further delay VER could run out of cash in 2019 and disaster looms! What disaster ???? IDIOTS abound.
hvs
23/11/2017
09:05
Just read the Edison note which emphasises the need for clarity for CP07/08 resubmission.If they can show a clear timetable so that ALL the remaining developments will be ready for the next year's season, that could spark a revival in the forecasts.If there is any further delay VER could run out of cash in 2019 and disaster looms!
fhmktg
23/11/2017
08:56
14th December for the agm....fgs I hope we get some clarity on how Tris are dealing with the fda issues or the strategy looks doubtful.
fhmktg
23/11/2017
08:48
A big negative is the level of cash burn ..with seemingly not much to show from it. I shall have a read of the Edison note.
meijiman
23/11/2017
08:27
Edison price target yesterday 68p...........would be nice....
chrisdgb
14/11/2017
11:20
desperately in need of some positive news here to reverse the slump
bountyhunter
14/11/2017
10:43
So you sold out and someone else kweeps buying. Good move.
hvs
30/10/2017
12:06
I recently reduced my holding here by over 60% as the opportunity arose to swap out the funds into Shire, with its share price severely down for no good reason it makes a lot of sense to do so - far more certainty of a recovery and profits at Shire than here. And CEO Flemming O is leagues ahead of this no hoper Ian Garland at Vernalis. Looks very much like Vernalis strategy is hostage to its partner Tris, with no control over what looks like an increasingly chaotic situation. Can only hope Vernalis is applying pressure but months on and still no word of progress. Strategy making less and less sense with ongoing cash burn at $20m but revenues just a few million, how can this ever make sense without more products hitting the market in a reasonable time.
romeike
27/10/2017
22:01
First post but thought this glassdoor review might give you a little insight in to tri pharma. Pros Mentally strengths you, so if you find yourself in a POW camp at some point - it will seem like a vacation... Cons I'm going to provide you with a realistic review of working at Tris Pharma, complete with actual facts (you know, those little pieces of knowledge that Tris fails to admit exist - like a Trump tax return). I served out my 3 year sentence and was finally released for early when the brainwashing and verbal beatings just stopped working. I don't know that I can describe in words what it is like to work for Tris, I would say it is something that needs to be experienced, but that's like saying one needs to experience drowning or burning alive. Sometimes you just have to believe its going to be unpleasant. Reading the past reviews, it is clear that the company has paid to have the positives ones written or more in line with Tris policy - forced employees to come to work on a federal holiday and write them for free. I do agree with the most recent review. This brings me to my first fact - turnover. Can you think of any other company that has a 90% plus turnover in management? and I'm talking senior management. These are successful people that have moved up the ranks at prestigious companies, some multiple billion dollar global organizations. For some reason, they just can't seem to or want to stay employed at Tris. Just so you don't think I'm making this up, here is just a partial list of the people who have come and gone at Tris over the last few years: Chief Scientific Officer Director of Finance Director of Supply Chain VP of Operations (1) VP of Operations (2) VP of Operations (3) VP of Quality (1) VP of Quality (2) Chief Business Officer Manager of Operations (1) Manager of Operations (2) Manager of Operations (3) Director of Quality Assurance Sr Manager of Compliance Sr Manager of Quality Control Supervisor Quality Control Supervisor Quality Control (2) VP of R&D (1) VP of R&D (2) Director of Method Development VP of Regulatory Sr. Manager of Regulatory Manager of Regulatory Manager of Packaging At least 8 purchasing employees - in a total group size of 3 Director of product Development VP of Sales VP Business Develpment Director of IT Manager of IT More operators, scientists, chemists, quality inspectors than I could possibly count. Now this is not a comprehensive list, but I can assure you it is factual. Can you think of any other organization in the world that can turnover this number of management positions in 4 years and still be successful? Keep in mind the company only had 50 - 200 total people during this time. Of course you can't. It isn't possible and that's why Tris isn't successful anymore either. Fact #2 - Sure things at Tris were going well for a while and the owner made a ton of money (fact #3 - check out the $10 million condo he bought last year in Miami, all while telling the employees that there is no money for raises or bonuses (again). Fact #4 - Take a look at Tris' partner Vernallis' stock. Went from $25 to $18 because of the poor FDA inspection Tris just had and an FDA letter they received, where their product was not approved. This comes as no surprise when you have an owner that is just about getting product out the door rather than assuring it is quality product. Hence all the recent recalls. Fact #5, #6, #7 - We have all seen foreign companies like this before and they always get what's coming to them. Tris is at that point. Tris is now in trouble with the FDA, its partners are not happy with them and will start leaving. The sales forces can't seem to get anything done and how can they with the shoe string budget they are given. Hard to sell $200 a bottle pills when you have to take customers to Bob's Big Boy for dinner. The worse employees will remain, the good ones have left or will leave. Talk to others in the pharmaceutical industry, they all know Tris and the CEO. Its like a red badge of courage to have put your time in and learned what not to do and how not to run a company. Soon they will have only the most incompetent people remaining and that will be the final straw in this long drawn out tragedy.... RIP
weber77
Chat Pages: 138  137  136  135  134  133  132  131  130  129  128  127  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180120 13:24:18